Fate Therapeutics (FATE) Change in Accured Expenses (2012 - 2026)
Fate Therapeutics (FATE) posted Change in Accured Expenses of -$5.8 million for Q1 2026, down 767.51% on a QoQ basis from $865000.0 in Q4 2025, and up 41.24% year-over-year from -$4.1 million in Q1 2025.
Fate Therapeutics (FATE) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Fate Therapeutics' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$5.8 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 41.24% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (up 28.72% YoY) and the FY2025 annual result came in at -$9.0 million, down 443.47% from the prior year.
- Change in Accured Expenses was -$5.8 million for Q1 2026 at Fate Therapeutics, down from $865000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $10.3 million in Q3 2022 and bottomed at -$20.4 million in Q1 2023.
- A 5-year average of -$1.8 million and a median of -$550000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 483.82% — and 2024, when it soared 182.03%.
- Fate Therapeutics' Change in Accured Expenses stood at $3.4 million in 2022, then tumbled by 155.89% to -$1.9 million in 2023, then jumped by 134.6% to $655000.0 in 2024, then soared by 32.06% to $865000.0 in 2025, then sank by 767.51% to -$5.8 million in 2026.
- Business Quant data shows FATE's Change in Accured Expenses at -$5.8 million in Q1 2026, $865000.0 in Q4 2025, and -$550000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.77 Mn |
| Mar 31, 2026 | -5.77 Mn |
| Dec 31, 2025 | 865,000.00 |
| Dec 31, 2025 | 865,000.00 |
| Sep 30, 2025 | -550,000.00 |
| Sep 30, 2025 | -550,000.00 |
| Jun 30, 2025 | 484,000.00 |
| Jun 30, 2025 | 484,000.00 |
| Mar 31, 2025 | -9.83 Mn |
| Mar 31, 2025 | -9.83 Mn |
| Dec 31, 2024 | 655,000.00 |
| Dec 31, 2024 | 655,000.00 |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 320,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | -4.51 Mn |
| Mar 31, 2024 | -4.51 Mn |
| Dec 31, 2023 | -1.89 Mn |
| Dec 31, 2023 | -1.89 Mn |